<DOC>
	<DOCNO>NCT02453464</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation study design assess safety , tolerability , pharmacokinetics Humanized Anti-VEGF Monoclonal Antibody ( Sevacizumab ) Injection combination FOLFIRI patient previously treat metastatic colorectal cancer . This study include two stage . Stage 1 dose-escalation stage . Once maximum tolerate dose ( MTD ) Sevacizumab establish , additional patient enrol cohort-expansion stage ( Stage 2 ) .</brief_summary>
	<brief_title>A Phase Ib Study Humanized Anti-VEGF Monoclonal Antibody ( Sevacizumab ) Injection Plus FOLFIRI Chinese Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histological/cytological confirm unresectable metastatic colorectal cancer patient fail firstline oxaliplatinbased chemotherapy At least one measurable lesion ( accord RECIST 1.1 ) At least 4 week last chemotherapy . If patient receive antitumor biological product , least four t1/2 washout period need Toxicity previous treatment restore ≤ grade 1 ( NCI CTC4.0 ) ECOG performance status 01 Life expectancy ≥ 3 month Adequate hematologic function : ANC ≥ 1.5 × 10^9 /L , HB ≥ 90 g /L ( blood transfusion allow ) , PLT ≥ 100 ×10^9 /L ; Adequate hepatic function : ALT ≤ 2.5 × ULN , AST ≤ 2.5 × ULN , TBIL ≤ 1.5 × ULN ( patient liver metastasis ALT ≤ 5 × ULN , AST ≤ 5 × ULN ) ; Adequate renal function : creatinine ≤ 1 × ULN ; Coagulation function : INR ≤ 1.5 × ULN , APTT ≤ 1.5 × ULN Patients childbearing potential ( male female ) must agree use reliable method contraception least 12 week last dose Patients sign write inform consent Willingness capability communicate investigator comply protocol requirement HCV , TP HIV antibody positive Previously receive antiVEGF protein drug , Bevacizumab , Sevacizumab Previously treat irinotecan History dihydropyrimidine dehydrogenase deficiency Patients alcohol drug dependence Participation clinical trial within 4 week enrollment Active chronic hepatitis B infection HBV DNA &gt; 1.0 * 10^3 IU/mL Serious infection require intravenous antibiotic therapy Symptomatic brain metastasis Patients proteinuria screen ( urine protein ≥ 1+ ) History abdominal fistula , gastrointestinal perforation , abdominal abscess within 6 month prior enrollment History intestinal obstruction , inflammatory bowel disease , intestinal disease chronic diarrhea major symptom Serious nonhealing wound , ulcer fracture Major surgery ( exclude biopsy ) significant trauma within 4 week prior enrollment Active bleeding within 3 month prior enrollment Bleeding diathesis coagulation disorder History arterial venous thrombosis History myocardial infarction stroke within 6 month prior enrollment Unstable angina , congestive heart failure , New York Heart Association ( NYHA ) class II heart failure , uncontrollable arrhythmia , uncontrolled hypertension Expected receive surgery study within 1 month last dose The investigator consider patient suitable trial Pregnant lactating woman Known allergy excipient study drug Patients complete study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>